Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu
Chronic hyperglycemia induces pathophysiologic pathways with negative effects on the metabolism of most substrates as well as lipids and lipoproteins, and thereby induces dyslipidemia. Thus, the diabetic milieu is commonly accompanied by different levels of atherogenic dyslipidemia, which is <i&g...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/21/6544 |
| _version_ | 1797467741801676800 |
|---|---|
| author | Habib Yaribeygi Mina Maleki Željko Reiner Tannaz Jamialahmadi Amirhossein Sahebkar |
| author_facet | Habib Yaribeygi Mina Maleki Željko Reiner Tannaz Jamialahmadi Amirhossein Sahebkar |
| author_sort | Habib Yaribeygi |
| collection | DOAJ |
| description | Chronic hyperglycemia induces pathophysiologic pathways with negative effects on the metabolism of most substrates as well as lipids and lipoproteins, and thereby induces dyslipidemia. Thus, the diabetic milieu is commonly accompanied by different levels of atherogenic dyslipidemia, which is <i>per se</i> a major risk factor for subsequent complications such as atherosclerosis, coronary heart disease, acute myocardial infarction, ischemic stroke, and nephropathy. Therefore, readjusting lipid metabolism in the diabetic milieu is a major goal for preventing dyslipidemia-induced complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a class of relatively newly introduced antidiabetes drugs (including empagliflozin, canagliflozin, dapagliflozin, etc.) with potent hypoglycemic effects and can reduce blood glucose by inducing glycosuria. However, recent evidence suggests that they could also provide extra-glycemic benefits in lipid metabolism. It seems that they can increase fat burning and lipolysis, normalizing the lipid metabolism and preventing or improving dyslipidemia. Nevertheless, the exact mechanisms involved in this process are not well-understood. In this review, we tried to explain how these drugs could regulate lipid homeostasis and we presented the possible involved cellular pathways supported by clinical evidence. |
| first_indexed | 2024-03-09T18:58:03Z |
| format | Article |
| id | doaj.art-cbaaeac5ba9e439691d30580d2a96a52 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T18:58:03Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-cbaaeac5ba9e439691d30580d2a96a522023-11-24T05:19:25ZengMDPI AGJournal of Clinical Medicine2077-03832022-11-011121654410.3390/jcm11216544Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic MilieuHabib Yaribeygi0Mina Maleki1Željko Reiner2Tannaz Jamialahmadi3Amirhossein Sahebkar4Research Center of Physiology, Semnan University of Medical Sciences, Semnan, IranUrology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Internal Medicine, University Hospital Center Zagreb, 1000 Zagreb, CroatiaApplied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, IranApplied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, IranChronic hyperglycemia induces pathophysiologic pathways with negative effects on the metabolism of most substrates as well as lipids and lipoproteins, and thereby induces dyslipidemia. Thus, the diabetic milieu is commonly accompanied by different levels of atherogenic dyslipidemia, which is <i>per se</i> a major risk factor for subsequent complications such as atherosclerosis, coronary heart disease, acute myocardial infarction, ischemic stroke, and nephropathy. Therefore, readjusting lipid metabolism in the diabetic milieu is a major goal for preventing dyslipidemia-induced complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a class of relatively newly introduced antidiabetes drugs (including empagliflozin, canagliflozin, dapagliflozin, etc.) with potent hypoglycemic effects and can reduce blood glucose by inducing glycosuria. However, recent evidence suggests that they could also provide extra-glycemic benefits in lipid metabolism. It seems that they can increase fat burning and lipolysis, normalizing the lipid metabolism and preventing or improving dyslipidemia. Nevertheless, the exact mechanisms involved in this process are not well-understood. In this review, we tried to explain how these drugs could regulate lipid homeostasis and we presented the possible involved cellular pathways supported by clinical evidence.https://www.mdpi.com/2077-0383/11/21/6544diabetes mellitussodium-glucose cotransporter-2 inhibitorslipidscholesterollipogenesislipolysis |
| spellingShingle | Habib Yaribeygi Mina Maleki Željko Reiner Tannaz Jamialahmadi Amirhossein Sahebkar Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu Journal of Clinical Medicine diabetes mellitus sodium-glucose cotransporter-2 inhibitors lipids cholesterol lipogenesis lipolysis |
| title | Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu |
| title_full | Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu |
| title_fullStr | Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu |
| title_full_unstemmed | Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu |
| title_short | Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu |
| title_sort | mechanistic view on the effects of sglt2 inhibitors on lipid metabolism in diabetic milieu |
| topic | diabetes mellitus sodium-glucose cotransporter-2 inhibitors lipids cholesterol lipogenesis lipolysis |
| url | https://www.mdpi.com/2077-0383/11/21/6544 |
| work_keys_str_mv | AT habibyaribeygi mechanisticviewontheeffectsofsglt2inhibitorsonlipidmetabolismindiabeticmilieu AT minamaleki mechanisticviewontheeffectsofsglt2inhibitorsonlipidmetabolismindiabeticmilieu AT zeljkoreiner mechanisticviewontheeffectsofsglt2inhibitorsonlipidmetabolismindiabeticmilieu AT tannazjamialahmadi mechanisticviewontheeffectsofsglt2inhibitorsonlipidmetabolismindiabeticmilieu AT amirhosseinsahebkar mechanisticviewontheeffectsofsglt2inhibitorsonlipidmetabolismindiabeticmilieu |